Source: Benzinga

electroCore: electroCore Extends VA Contract for Five Years

ROCKAWAY, N.J., March 31, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (NASDAQ:ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that electroCore has received a new Federal Supply Schedule (FSS) contract, with an effective date of June 15, 2025 and running through June 14, 2030."Obtaining a follow-on contract in this macro environment is a tremendous vote of confidence by the Veterans Affairs (VA) FSS Service, demonstrating that gammaCore continues to be a cost effective therapeutic benefiting our veterans," commented Dan Goldberger, Chief Executive Officer of electroCore. "VA Hospital revenue accelerated in February and March, after modest slowing in January 2025, reflecting continued demand for this drug-free method for addressing migraine headaches."Mr. Goldberger continued, "On March 3, 2025, the VA terminated 585 non-mission critical or duplicative contracts following review by the new administration. This award of a new, five-year contract following such an audit further validates the value we provide the VA system and our veterans. We are greatly appreciative of the support we received during this two-year process from our FSS contract officer in ensuring our veterans have access to our non-opioid pain solution." ...Full story available on Benzinga.com

Read full article »
Annual Revenue
$25-100M
Employees
25-100
Daniel S Goldberger's photo - CEO of electroCore

CEO

Daniel S Goldberger

CEO Approval Rating

90/100

Read more